Biosimilar drugs enter the United States market well after they enter the European market. That is likely because pharmaceutical companies have many more patents in the United States than in Europe. But why is patent coverage of biological drugs so much more extensive in United States? This case study seeks to answer this question for drug formulation patents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/jme.2024.132 | DOI Listing |
Publication Analysis
Top Keywords
united states
8
uspto's lax
4
lax policy
4
policy leads
4
leads humira
4
humira formulation
4
formulation thicket
4
thicket biosimilar
4
biosimilar drugs
4
drugs enter
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!